Sensei Biotherapeutics, Inc. (SNSE)

They are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Their proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. They are currently conducting an ongoing 30-patient Phase 1/2 clinical trial of their lead product candidate, SNS-301, in combination with the PD-1 inhibitor pembrolizumab, as a potential treatment for squamous cell carcinoma of the head and neck, or SCCHN. As of December 10, 2020, they have enrolled 11 patients in the trial, of which ten patients were evaluable for efficacy. They have observed disease control in seven of the patients evaluable for efficacy, including one patient with a partial response, or PR, and two patients who have achieved longstanding stable disease, or SD, for greater than 36 weeks following treatment. Treatment with SNS-301 has generally been well tolerated. They anticipate reporting topline data from this trial by the end of 2021. If the results of this trial are positive, subject to feedback from the U.S. Food and Drug Administration, or FDA, they intend to initiate a randomized, registration-enabling trial for SNS-301.

Industry
Pharmaceuticals

CEO	CFO
John Celebi	Erin Colgan

John Celebi has served as our President and Chief Executive Officer and a member of our board of directors since February 2018. Prior to joining us, from June 2016 until February 2018, Mr. Celebi served as Chief Operating Officer of X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. Prior to X4 Pharmaceuticals, from 2011 until June 2016, he served as Chief Business Officer at Igenica Biotherapeutics, Inc., an immunotherapy company. Prior to joining Igencia Biotherapeutics, Mr. Celebi served in various roles at ArQule, Inc., a biotechnology and pharmaceutical company from 2003 until 2011, including as Vice President of Business Development and New Product Planning and Alliance Management. Mr. Celebi received a B.S. in Biophysics from the University of California, San Diego and an M.B.A. from Carnegie Mellon University. We believe that Mr. Celebi’s perspective and deep experience in the biotechnology industry, as well as his experience leading our company as the President and Chief Executive Officer, qualifies him to serve on our board of directors.

Erin Colgan has served as our Senior Vice President of Finance since January 2021 and previously served as our Vice President of Finance from July 2020 to January 2021. Prior to joining us, Ms. Colgan served as the Vice President of FP+A and Commercial Planning at Intarcia Therapeutics from August 2019 to June 2020. Prior to Intarcia, from August 2010 to August 2019, Ms. Colgan held various roles of increasing responsibility at Vertex Pharmaceuticals, most recently as Senior Director, FP+A and Global Revenue. Ms. Colgan began her career in public accounting at PricewaterhouseCoopers where she worked in both audit and business development. Ms. Colgan holds a B.A. in Accounting from the University of Massachusetts, Amherst.

Employees	Founded
24	1999

Address: 1405 Research Blvd, Suite 125 Rockville, MD 20850

Telephone: (240) 243-8000

Web page: http://www.senseibio.com

Expected Date	2/4/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the SNSE share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Citigroup

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Citigroup/ Piper Sandler/ Berenberg
CO-Managers
Oppenheimer